## Marieke W J Louwman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1922088/publications.pdf

Version: 2024-02-01

134 papers 6,841 citations

41 h-index 73587 **79** g-index

145 all docs 145 docs citations

145 times ranked 9086 citing authors

#	Article	IF	CITATIONS
1	A nationwide study of the incidence and trends of first and multiple basal cell carcinomas in the Netherlands and prediction of future incidence*. British Journal of Dermatology, 2022, 186, 476-484.	1.4	10
2	The impact of the COVIDâ€19 pandemic on keratinocyte carcinoma in the Netherlands: Trends in diagnoses and magnitude of diagnostic delays. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 680-687.	1.3	16
3	Limited impact of <scp>COVID</scp> â€19â€related diagnostic delay on cutaneous melanoma and squamous cell carcinoma tumour characteristics: a nationwide pathology registry analysis. British Journal of Dermatology, 2022, 187, 196-202.	1.4	17
4	Basal cell carcinoma, an often unjustly overlooked healthcare challenge. British Journal of Dermatology, 2022, , .	1.4	0
5	Skin melanoma deaths within 1 or 3 years from diagnosis in Europe. International Journal of Cancer, 2021, 148, 2898-2905.	2.3	7
6	Letter in reply: increase of sentinel lymph node melanoma staging in The Netherlands; still room and need for further improvement. Melanoma Management, 2021, 8, MMT53.	0.1	0
7	Survival of sentinel node biopsy versus observation in intermediate-thickness melanoma: A Dutch population-based study. PLoS ONE, 2021, 16, e0252021.	1.1	6
8	Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003–2018): A nationwide population-based study. European Journal of Cancer, 2021, 154, 111-119.	1.3	16
9	Primary Melanoma Characteristics of Metastatic Disease: A Nationwide Cancer Registry Study. Cancers, 2021, 13, 4431.	1.7	12
10	The Risk of Cutaneous Squamous Cell Carcinoma Among Patients with Type 2 Diabetes Receiving Hydrochlorothiazide: A Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2114-2121.	1.1	5
11	Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch populationâ€based study. International Journal of Cancer, 2020, 146, 26-34.	2.3	28
12	Health-Related Quality of Life, Satisfaction with Care, and Cosmetic Results in Relation to Treatment among Patients with Keratinocyte Cancer in the Head and Neck Area: Results from the PROFILES Registry. Dermatology, 2020, 236, 133-142.	0.9	9
13	Melanoma in older patients: declining gap in survival between younger and older patients with melanoma. Acta Oncol $ ilde{A}^3$ gica, 2020, 59, 4-12.	0.8	9
14	Incidence of Multiple vs First Cutaneous Squamous Cell Carcinoma on a Nationwide Scale and Estimation of Future Incidences of Cutaneous Squamous Cell Carcinoma. JAMA Dermatology, 2020, 156, 1300.	2.0	44
15	Assessment of Cutaneous Squamous Cell Carcinoma (cSCC) In situ Incidence and the Risk of Developing Invasive cSCC in Patients With Prior cSCC In situ vs the General Population in the Netherlands, 1989-2017. JAMA Dermatology, 2020, 156, 973.	2.0	22
16	Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncology, The, 2020, 21, 750-751.	5.1	454
17	Increase of sentinel lymph node melanoma staging in The Netherlands; still room and need for further improvement. Melanoma Management, 2020, 7, MMT38.	0.1	6
18	Increasing Costs of Skin Cancer due to Increasing Incidence and Introduction of Pharmaceuticals, 2007–2017. Acta Dermato-Venereologica, 2020, 100, adv00147.	0.6	15

#	Article	IF	CITATIONS
19	Characteristics of screen-detected cancers following concordant or discordant recalls at blinded double reading in biennial digital screening mammography. European Radiology, 2019, 29, 337-344.	2.3	3
20	Author's reply to: The realâ€world outcome of metastatic melanoma: Unknown primary <i>vs</i> known cutaneous. International Journal of Cancer, 2019, 145, 3175-3176.	2.3	1
21	Metastatic Uveal Melanoma: Treatment Strategies and Survivalâ€"Results from the Dutch Melanoma Treatment Registry. Cancers, 2019, 11, 1007.	1.7	22
22	Sex matters: men with melanoma have a worse prognosis than women. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2062-2067.	1.3	28
23	Treatment and survival of Merkel cell carcinoma since 1993: A population-based cohort study in The Netherlands. Journal of the American Academy of Dermatology, 2019, 81, 977-983.	0.6	8
24	PCN119 RISING REIMBURSED COSTS OF BENIGN AND (PRE) MALIGNANT SKIN TUMORS DUE TO INCREASING INCIDENCE AND INTRODUCTION OF PHARMACEUTICALS IN THE NETHERLANDS, 2007-2016. Value in Health, 2019, 22, S78.	0.1	0
25	Opportunities for improving the efficiency of keratinocyte carcinoma care in primary and specialist care: Results from population-based Dutch cohort studies. European Journal of Cancer, 2019, 117, 32-40.	1.3	9
26	Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. Anti-Cancer Drugs, 2018, 29, 579-588.	0.7	11
27	Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. Anti-Cancer Drugs, 2018, 29, 572-578.	0.7	11
28	Trends in incidence of thick, thin and in situ melanoma in Europe. European Journal of Cancer, 2018, 92, 108-118.	1.3	155
29	Incidence and tumour characteristics of bilateral and unilateral interval breast cancers at screening mammography. Breast, 2018, 38, 101-106.	0.9	8
30	Frequency and characteristics of contralateral breast abnormalities following recall at screening mammography. European Radiology, 2018, 28, 4205-4214.	2.3	3
31	Improved stratification of pT1 melanoma according to the 8th American Joint Committee on Cancer staging edition criteria: A Dutch population-based study. European Journal of Cancer, 2018, 92, 100-107.	1.3	8
32	Tumour characteristics of bilateral screen-detected cancers and bilateral interval cancers in women participating at biennial screening mammography. European Journal of Radiology, 2018, 108, 215-221.	1.2	1
33	Sinonasal cancer in The Netherlands: Followâ€up of a populationâ€based study 1989â€2014 and incidence of occupationâ€related adenocarcinoma. Head and Neck, 2018, 40, 2462-2468.	0.9	7
34	Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes. Melanoma Research, 2018, 28, 326-332.	0.6	8
35	Impact of the second reader on screening outcome at blinded double reading of digital screening mammograms. British Journal of Cancer, 2018, 119, 503-507.	2.9	20
36	Quality assurance in melanoma care: The EU-MELACARE study. European Journal of Surgical Oncology, 2018, 44, 1773-1778.	0.5	3

#	Article	IF	Citations
37	Incorporation of the technologist's opinion for arbitration of discrepant assessments among radiologists at screening mammography. Breast Cancer Research and Treatment, 2018, 171, 143-149.	1.1	2
38	Implementation of the 7th edition <scp>AJCC</scp> staging system: Effects on staging and survival for pT1 melanoma. A Dutch population based study. International Journal of Cancer, 2017, 140, 1802-1808.	2.3	10
39	Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors. British Journal of Cancer, 2017, 117, 306-314.	2.9	26
40	Implementation of the 7th edition AJCC staging system: effects on staging and survival for pT1 melanoma. A Dutch population based study. European Journal of Cancer, 2017, 72, S127.	1.3	0
41	Practice variation in Sentinel Lymph Node Biopsy for melanoma patients in different geographical regions in the Netherlands. Surgical Oncology, 2017, 26, 431-437.	0.8	10
42	Interval breast cancer characteristics before, during and after the transition from screen-film to full-field digital screening mammography. BMC Cancer, 2017, 17, 315.	1.1	10
43	Healthcare Costs of Ipilimumab in Patients with Advanced Cutaneous Melanoma in Dutch Clinical Practice. Value in Health, 2017, 20, A431.	0.1	O
44	Real-world survival results of metastatic melanoma patients treated with ipilimumab in the Netherlands. Annals of Oncology, 2016, 27, vi384.	0.6	0
45	Survival in BRAF-mutant metastatic melanoma in the real-world setting: results from the Dutch Melanoma Treatment Registry. Annals of Oncology, 2016, 27, vi390.	0.6	O
46	Real-World Outcomes of Ipilimumab in Patients with Advanced Melanoma in The Netherlands. Value in Health, 2016, 19, A708-A709.	0.1	0
47	Real-World Outcomes of Novel Treatments in Patients with Advanced Melanoma in The Netherlands. Value in Health, 2016, 19, A709.	0.1	O
48	External Validity at Stake in Mapping Non-Preference Based Disease Specific Measures to Generic Preference-Based Utility Values in Advanced Cutaneous Melanoma. Value in Health, 2016, 19, A384.	0.1	0
49	Healthcare Resource Use Alongside Novel Treatments for Advanced Melanoma in the Netherlands. Value in Health, 2016, 19, A742.	0.1	O
50	Informal Care and Productivity Losses are Important in Advanced Cutaneous Melanoma: Results of the Dutch Melanoma Treatment Registry. Value in Health, 2016, 19, A745-A746.	0.1	0
51	Quality of Life in Advanced Melanoma: Results of The Dutch Melanoma Treatment Registry. Value in Health, 2016, 19, A747.	0.1	O
52	Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. New England Journal of Medicine, 2015, 373, 2499-2511.	13.9	474
53	EUROCOURSE recipe for cancer surveillance by visible population-based cancer RegisTrees® in Europe: From roots to fruits. European Journal of Cancer, 2015, 51, 1050-1063.	1.3	18
54	Uses of cancer registries for public health and clinical research in Europe: Results of the European Network of Cancer Registries survey among 161 population-based cancer registries during 2010–2012. European Journal of Cancer, 2015, 51, 1039-1049.	1.3	77

#	Article	IF	CITATIONS
55	Impact of the transition from screen-film to digital screening mammography on interval cancer characteristics and treatment $\hat{a} \in A$ population based study from the Netherlands. European Journal of Cancer, 2014, 50, 31-39.	1.3	37
56	Time trends and inter-hospital variation in treatment and axillary staging of patients with ductal carcinoma in situ of the breast in the era of screening in Southern Netherlands. Breast, 2014, 23, 63-68.	0.9	15
57	Risk of multiple primary malignancies following treatment of Hodgkin lymphoma. Blood, 2014, 124, 319-327.	0.6	58
58	The Impact of Socioeconomic Status on Prostate Cancer Treatment and Survival in the Southern Netherlands. Urology, 2013, 81, 593-601.	0.5	44
59	Trends in breast biopsies for abnormalities detected at screening mammography: a population-based study in the Netherlands. British Journal of Cancer, 2013, 109, 242-248.	2.9	20
60	Small but significant socioeconomic inequalities in axillary staging and treatment of breast cancer in the Netherlands. British Journal of Cancer, 2012, 107, 12-17.	2.9	18
61	Risk and prognostic significance of metachronous contralateral testicular germ cell tumours. British Journal of Cancer, 2012, 107, 1637-1643.	2.9	27
62	Impact of transition from analog screening mammography to digital screening mammography on screening outcome in The Netherlands: a population-based study. Annals of Oncology, 2012, 23, 3098-3103.	0.6	57
63	Characteristics and screening outcome of women referred twice at screening mammography. European Radiology, 2012, 22, 2624-2632.	2.3	2
64	Mammographic changes resulting from benign breast surgery impair breast cancer detection at screening mammography. European Journal of Cancer, 2012, 48, 2097-2103.	1.3	16
65	Trends in sinonasal cancer in The Netherlands: More squamous cell cancer, less adenocarcinoma. European Journal of Cancer, 2012, 48, 2369-2374.	1.3	63
66	Progress against cancer in the Netherlands since the late 1980s: An epidemiological evaluation. International Journal of Cancer, 2012, 130, 2981-2989.	2.3	37
67	Malpractice claims following screening mammography in The Netherlands. International Journal of Cancer, 2012, 131, 1360-1366.	2.3	16
68	Mapping Use of Radiotherapy for Patients with Non-small Cell Lung Cancer in the Netherlands between 1997 and 2008. Clinical Oncology, 2012, 24, e46-e53.	0.6	12
69	Use of Primary Radiotherapy for Rectal Cancer in the Netherlands between 1997 and 2008: A Population-based Study. Clinical Oncology, 2012, 24, e1-e8.	0.6	14
70	Trends in incidence and detection of advanced breast cancer at biennial screening mammography in The Netherlands: a population based study. Breast Cancer Research, 2012, 14, R10.	2.2	54
71	Lower sensitivity of screening mammography after previous benign breast surgery. International Journal of Cancer, 2012, 130, 122-128.	2.3	13
72	INCREASED RISK OF GASTROINTESTINAL CANCER IN HODGKIN LYMPHOMA PATIENTS: A DUTCH LONG-TERM FOLLOW-UP STUDY. Radiotherapy and Oncology, 2011, 98, S14.	0.3	0

#	Article	IF	Citations
73	An increased utilisation rate and better compliance to guidelines for primary radiotherapy for breast cancer from 1997 till 2008: A population-based study in The Netherlands. Radiotherapy and Oncology, 2011, 100, 320-325.	0.3	20
74	A population-based study on the utilisation rate of primary radiotherapy for prostate cancer in 4 regions in the Netherlands, 1997–2008. Radiotherapy and Oncology, 2011, 99, 207-213.	0.3	10
75	Variation in cancer incidence in northeastern Belgium and southeastern Netherlands seems unrelated to cadmium emission of zinc smelters. European Journal of Cancer Prevention, 2011, 20, 549-555.	0.6	10
76	Socioeconomic inequalities in attending the mass screening for breast cancer in the south of the Netherlands—associations with stage at diagnosis and survival. Breast Cancer Research and Treatment, 2011, 128, 517-525.	1.1	69
77	Patient and tumor characteristics of bilateral breast cancer at screening mammography in the Netherlands, a population-based study. Breast Cancer Research and Treatment, 2011, 129, 955-961.	1.1	14
78	Prevalence of multiple malignancies in the Netherlands in 2007. International Journal of Cancer, 2011, 128, 1659-1667.	2.3	45
79	Detection of Bilateral Breast Cancer at Biennial Screening Mammography in the Netherlands: A Population-based Study. Radiology, 2011, 260, 357-363.	3.6	13
80	Scrotal cancer: incidence, survival and second primary tumours in the Netherlands since 1989. British Journal of Cancer, 2010, 103, 1462-1466.	2.9	39
81	A 50% higher prevalence of life-shortening chronic conditions among cancer patients with low socioeconomic status. British Journal of Cancer, 2010, 103, 1742-1748.	2.9	141
82	Epidemiology of Extracutaneous Melanoma in the Netherlands. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1453-1459.	1.1	32
83	Incidence and Trends of Cutaneous Malignancies in the Netherlands, 1989–2005. Journal of Investigative Dermatology, 2010, 130, 1807-1812.	0.3	104
84	Socioeconomic status and changing inequalities in colorectal cancer? A review of the associations with risk, treatment and outcome. European Journal of Cancer, 2010, 46, 2681-2695.	1.3	203
85	Reduction of socioeconomic inequality in cancer incidence in the South of the Netherlands during 1996–2008. European Journal of Cancer, 2010, 46, 2633-2646.	1.3	44
86	Clinical Epidemiology and the Impact of Co-Morbidity on Survival. , 2010, , 37-50.		0
87	Screening caused rising incidence rates of ductal carcinoma inÂsitu of the breast. Breast Cancer Research and Treatment, 2009, 115, 181-183.	1.1	51
88	Increase in basal cell carcinoma incidence steepest in individuals with high socioeconomic status: results of a cancer registry study in the Netherlands. British Journal of Dermatology, 2009, 161, 840-845.	1.4	46
89	Rising incidence of breast cancer among female cancer survivors: implications for surveillance. British Journal of Cancer, 2009, 100, 77-81.	2.9	3
90	Population-Based Study of Trends and Variations in Radiotherapy as Part of Primary Treatment of Cancer in the Southern Netherlands Between 1988 and 2006, With an Emphasis on Breast and Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 74, 464-471.	0.4	15

#	Article	IF	Citations
91	3501 Progress against cancer in the Netherlands since the 1990 s: an epidemiological evaluation. European Journal of Cancer, Supplement, 2009, 7, 202.	2.2	O
92	General practitioners and referral for palliative radiotherapy: A population-based survey. Radiotherapy and Oncology, 2009, 91, 267-270.	0.3	23
93	7101 Risk of metachronous contralateral testicular cancer (CTC) among 3,745 Dutch men diagnosed during 1965–1995. European Journal of Cancer, Supplement, 2009, 7, 423.	2.2	O
94	Breast Cancer Risk in Female Survivors of Hodgkin's Lymphoma: Lower Risk After Smaller Radiation Volumes. Journal of Clinical Oncology, 2009, 27, 4239-4246.	0.8	324
95	Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood, 2009, 113, 3679-3681.	0.6	72
96	An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Research and Treatment, 2008, 107, 309-330.	1.1	396
97	The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Research and Treatment, 2008, 110, 189-197.	1.1	97
98	On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975–2004: a long-term population-based study in southeastern Netherlands. Cancer Causes and Control, 2008, 19, 97-106.	0.8	64
99	Childhood social class and cancer incidence: Results of the globe study. Social Science and Medicine, 2008, 66, 1131-1139.	1.8	60
100	Are Patients with Skin Cancer at Lower Risk of Developing Colorectal or Breast Cancer?. American Journal of Epidemiology, 2008, 167, 1421-1429.	1.6	44
101	Risk of New Primary Nonbreast Cancers After Breast Cancer Treatment: A Dutch Population-Based Study. Journal of Clinical Oncology, 2008, 26, 1239-1246.	0.8	181
102	Does the Decrease in Hormone Replacement Therapy Also Affect Breast Cancer Risk in the Netherlands?. Journal of Clinical Oncology, 2007, 25, 5038-5039.	0.8	47
103	Decreased Risk of Prostate Cancer after Skin Cancer Diagnosis: A Protective Role of Ultraviolet Radiation?. American Journal of Epidemiology, 2007, 165, 966-972.	1.6	78
104	Oesophageal cancer in The Netherlands: Increasing incidence and mortality but improving survival. European Journal of Cancer, 2007, 43, 1445-1451.	1.3	39
105	A population based study of radiotherapy in a cohort of patients with breast cancer diagnosed between 1996 and 2000. European Journal of Cancer, 2007, 43, 1976-1982.	1.3	3
106	Clinical epidemiology of breast cancer in the elderly. European Journal of Cancer, 2007, 43, 2242-2252.	1.3	77
107	A population-based study of radiotherapy in a cohort of patients with rectal cancer diagnosed between 1996 and 2000. European Journal of Surgical Oncology, 2007, 33, 993-997.	0.5	10
108	Treatment-Specific Risks of Second Malignancies and Cardiovascular Disease in 5-Year Survivors of Testicular Cancer. Journal of Clinical Oncology, 2007, 25, 4370-4378.	0.8	403

#	Article	IF	CITATIONS
109	Uncommon breast tumors in perspective: Incidence, treatment and survival in the Netherlands. International Journal of Cancer, 2007, 121, 127-135.	2.3	114
110	Impact of a programme of mass mammography screening for breast cancer on socio-economic variation in survival: a population-based study. Breast Cancer Research and Treatment, 2007, 105, 369-375.	1.1	42
111	Referral rates and trends in radiotherapy as part of primary treatment of cancer in South Netherlands, 1988–2002. Radiotherapy and Oncology, 2006, 78, 131-137.	0.3	27
112	Increased risk of second malignancies after in situ breast carcinoma in a population-based registry. British Journal of Cancer, 2006, 95, 393-397.	2.9	25
113	The influence of age and comorbidity on receiving radiotherapy as part of primary treatment for cancer in South Netherlands, 1995 to 2002. Cancer, 2006, 106, 2734-2742.	2.0	84
114	Long-term survival of T1 and T2 lymph node-negative breast cancer patients according to mitotic activity index: A population-based study. International Journal of Cancer, 2006, 118, 2310-2314.	2.3	9
115	Predictions of skin cancer incidence in the Netherlands up to 2015. British Journal of Dermatology, 2005, 152, 481-488.	1.4	230
116	Prognostic impact of increasing age and co-morbidity in cancer patients: A population-based approach. Critical Reviews in Oncology/Hematology, 2005, 55, 231-240.	2.0	333
117	Primary Malignancy after Primary Female Breast Cancer in the South of the Netherlands, 1972–2001. Breast Cancer Research and Treatment, 2005, 93, 91-95.	1.1	62
118	Age and Co-Morbidity in Cancer Patients: A Population-Based Approach. , 2005, 124, 89-107.		28
119	Hypothyroidism Might Be Related to Breast Cancer in Post-Menopausal Women. Thyroid, 2005, 15, 1253-1259.	2.4	105
120	Increasing incidence and improved survival of cancer in children and young adults in Southern Netherlands, 1973–1999. European Journal of Cancer, 2005, 41, 760-769.	1.3	25
121	Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: A population-based study. European Journal of Cancer, 2005, 41, 779-785.	1.3	197
122	Risks of second primary breast and urogenital cancer following female breast cancer in the south of The Netherlands, 1972–2001. European Journal of Cancer, 2005, 41, 2331-2337.	1.3	40
123	Hospital variation in referral for primary radiotherapy in South Netherlands, 1988–1999. European Journal of Cancer, 2005, 41, 2722-2727.	1.3	19
124	Hypertension as a risk factor for glioma? Evidence from a population-based study of comorbidity in glioma patients. Annals of Oncology, 2004, 15, 1256-1260.	0.6	17
125	Determinants of Prognosis in Breast Cancer Patients with Tumor Involvement of the Skin (pT4b). Breast Journal, 2004, 10, 123-128.	0.4	28
126	Rapid and Continuous Increases in Incidence Rates of Basal Cell Carcinoma in the Southeast Netherlands Since 1973. Journal of Investigative Dermatology, 2004, 123, 634-638.	0.3	137

#	ARTICLE	IF	CITATIONS
127	Comorbidity has negligible impact on treatment and complications but influences survival in breast cancer patients. British Journal of Cancer, 2004, 90, 2332-2337.	2.9	97
128	Stable overall referral rates of primary radiotherapy for newly diagnosed cancer patients in the ageing population of South-Eastern Netherlands, 1975–1998. Radiotherapy and Oncology, 2004, 73, 101-108.	0.3	13
129	Behaviour partly explains educational differences in cancer incidence in the south-eastern Netherlands: the longitudinal GLOBE study. European Journal of Cancer Prevention, 2004, 13, 119-125.	0.6	28
130	Depression and the lower risk for breast cancer development in middle-aged women: a prospective study. Psychological Medicine, 2003, 33, 1111-1117.	2.7	22
131	Increased incidence of adenocarcinomas at the gastro-oesophageal junction in Dutch males since the 1990s. European Journal of Gastroenterology and Hepatology, 2002, 14, 115-122.	0.8	58
132	Trends in Breast Cancer Aggressiveness Before the Introduction of Mass Screening in Southeastern Netherlands 1975–1989. Breast Cancer Research and Treatment, 2002, 73, 199-206.	1,1	7
133	Excess mortality from breast cancer 20 years after diagnosis when life expectancy is normal. British Journal of Cancer, 2001, 84, 700-703.	2.9	27
134	Signs of impaired cognitive function in adolescents with marginal cobalamin status. American Journal of Clinical Nutrition, 2000, 72, 762-769.	2.2	150